Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 755-763

  Tsukada, Hideo ^a   Ohba, Hiroyuki ^a   Kanazawa, Masakatsu ^a   Kakiuchi, Takeharu ^a   Harada, Norihiro ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Aging; Brain; Mitochondrial complex I; PET; Rotenone

Indexed keywords

2 TERT BUTYL 4 CHLORO 5 [6 [2 (2 FLUOROETHOXY) ETHOXY] PYRIDIN 3 YLMETHOXY] 2H PYRIDAZIN 3 ONE F 18; PYRIDAZINE DERIVATIVE; PYRIDOXAL 5 PHOSPHATE; RADIOPHARMACEUTICAL AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG; 2-TERT-BUTYL-4-CHLORO-5-(6-(2-(2-FLUOROETHOXY)ETHOXY)PYRIDIN-3-YLMETHOXY)-2H-PYRIDAZIN-3-ONE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CEREBELLUM; COMPARTMENT MODEL; CORPUS STRIATUM; DISTRIBUTION VOLUME; DRUG BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG UPTAKE; ENZYME ACTIVITY; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; MALE; METABOLIC RATE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; RHESUS MONKEY; TEMPORAL CORTEX; TRANSLATIONAL RESEARCH; ANIMAL; BRAIN; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; ELECTRON TRANSPORT COMPLEX I; MACACA MULATTA; POSITRON-EMISSION TOMOGRAPHY; PYRIDAZINES; PYRIDINES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84897024490     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2628-z     Document Type: Article

References (37)

1. Meisenzahl EM, Schmitt GJ, Scheuerecker J, Möller HJ. The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry. 2007;19:337-45. (Pubitemid 47206979)
2. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry. 2006;59:919-28.
3. Brooke DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51:596-609.
4. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009;8:1158-71.
5. Kadir A, Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med. 2010;51: 1418-30.
6. Neyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012;91:201-14.
7. 18F] FDG-PET study. J Cereb Blood Flow Metab. 2009;29:1216-25.
8. Fukumoto D, Hosoya T, Nishiyama S, Harada N, Iwata H, Yamamoto S, et al. Multiparametric assessment of acute and subacute ischemic neuronal damage: a small animal PET study with rat photochemically induced thrombosis (PIT) model. Synapse. 2011;65:207-14.
9. Winkeler A, Boisgard R, Martin A, Tavitian B. Radioisotopic imaging of neuroinflammation. J Nucl Med. 2010;51:1-4.
10. Jacobs AH, Tavitian B, INMiND Consortium. Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32:1393-415.
11. Purohit A, Radeke H, Azure M, Hanson K, Benetti R, Su F, et al. Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers. J Med Chem. 2008;51:2954-70. (Pubitemid 351706024)
12. Yalamanchili P, Wexler E, Hayes M, Yu M, Bozek J, Kagan M, et al. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol. 2007;14:782-8. (Pubitemid 350082573)
13. 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49:630-6.
14. 18F]BMS-747158-02, amitochondrial complex-1 PET ligand: small animal PETstudy in rat brain. Synapse. 2012;66:909-17.
15. 11C]BCPPEM for mitochondrial complex 1 imaging in the living brain. J Label Compd Radiopharm. 2013;56:553-61.
16. Noda A, Takamatsu H, Minoshima S, Tsukada H, Nishimura S. Determination of kinetic rate constants for FDG and partition coefficient of water in conscious macaque and alterations in aging or anesthesia examined on parametric images with an anatomic standardization technique. J Cereb Blood Flow Metab. 2003;23:1441-7. (Pubitemid 38018262)
17. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover? Positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci. 2000;20:7067-73.
18. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci. 1997;44:1277-82. (Pubitemid 127827087)
19. Jones EG, Stone JM, Karten HJ. High-resolution digital brain atlases: a Hubble telescope for the brain. Ann N YAcad Sci. 2011;1225(S1):E147-59.
20. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-7.
21. Huang SH, Barrio J, Phelps M. Neuroreceptor assay with positron emission tomography; equilibrium versus dynamic approach. J Cereb Blood Flow Metab. 1986;6:515-21. (Pubitemid 17198734)
22. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-27. (Pubitemid 14164735)
23. Phelps ME. PET molecular imaging and its biological applications. New York: Springer; 2004. p. 125-216.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716-23.
25. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376-89. (Pubitemid 37489828)
26. 18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab. 1998;18:1130-42.
27. 11C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse. 2001;40:159-69.
28. Koeppe RA, Frey KA, Mulholland GK, Kilbourn MR, Buck A, Lee KS, et al. [11C]Tropanyl benzilate binding to muscarinic cholinergic receptors: methodology and kinetic modeling alterations. J Cereb Blood Flow Metab. 1994;14:85-99.
29. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
30. 11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab. 1994;14:995-1010.
31. Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest. 2013;123:951-7.
32. Cadenas E, Boveris A, Ragan CI, Stoppani AOM. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys. 1977;180:248-57. (Pubitemid 8115490)
33. Ojaimi J, Masters CL, Opeskin K, McKelvie P, Byrne E. Mitochondrial respiratory chain activity in the human brain as a function of age. Mech Ageing Dev. 1999;111:39-47. (Pubitemid 29486435)
34. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol. 2007;292:C670-86.
35. Raha S, Robinson BH. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci. 2000;25:502-8.
36. Manczak M, Jung Y, Park BS, Partovi D, Reddy PH. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem. 2005;92:494-504. (Pubitemid 40189453)
37. Benzi G, Pastoris O, Marzatico F, Villa RF, Dagani F, Curti D. The mitochondrial electron transfer alteration as a factor involved in the brain aging. Neurobiol Age. 1992;13:361-8.